BACKGROUND: The bacterium Escherichia coli is a commonly used host for the production of recombinant protein biopharmaceutical products. One class of such molecules is antibody fragments, typified by the Crohn's disease and rheumatoid arthritis therapy Certolizumab pegol (Cimzia ® ). Antibody fragments generated in E. coli are often directed to the periplasm, so that disulphide bonding can occur and release can be simplified. However, many recombinant protein products are prone to misfolding and mislocalization. Here, we optimized the production of a Fab fragment, D1.3, and its release from the periplasm of E. coli using osmotic shock.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.